ClinicalTrials.gg
CompletedNCT00659659Updated Oct 10, 2012

A Study to Evaluate the Safety, Tolerability and Effects of MEDI-563 in Adults With Asthma

A Phase 1 interventional study of MEDI-563 and MEDI-563 in Asthma, sponsored by MedImmune LLC. Completed at 11 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-10-10.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.

Enrollment
35th of 39
27 · median 128
Started
2008
with 1 other
Phase 1
3 of 39
none open now
Registered
2nd of 39
by date
Lead sponsor
5 of 39
MedImmune LLC

Among the 39 studies testing benralizumab in Asthma, this one is the 35th largest by enrollment, is one of 2 that started in 2008, is one of 3 in phase 1, and was the 2nd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About benralizumab

benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing benralizumab in Asthma, or all of them as a file.
02

Study summary

Evaluate the safety and tolerability of MEDI-563 in adults with asthma and the effects of MEDI-563 on eosinophil counts in airway mucosal biopsies

Read the detailed description

Evaluate the safety and tolerability of MEDI-563 in adults with atopic asthma; and evaluate the effects of MEDI-563 on eosinophil counts in airway mucosal biopsies 28 days after completion of dosing in adults with atopic asthma.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female adults, 18 through 65 years of age at time of randomization;
  • Written obtained from the subject prior to beginning study procedures or receipt of any study medication;
  • Previously documented diagnosis of asthma of ≥ 1 year duration, based on episodic symptoms of airflow obstruction; post-bronchodilator reversibility of airflow obstruction ≥ 12% (in USA only - if subject does not achieve this during screening, proof of ≥12% reversibility within 1 year of randomization is acceptable) or proof of a positive response to a methacholine challenge during screening with prior approval from MedImmune (in USA only - within 1 year of randomization is acceptable) as represented by a provoking concentration of methacholine to cause a 20% fall in (PC20) \< 8 mg/ml [American Thoracic Society (ATS), 2000)]; and exclusion of alternative pulmonary diagnoses (eg, cystic fibrosis, );
  • Asthma symptoms are adequately controlled on a therapeutic regimen that has not changed in the last 4 weeks prior to Study Day 0, and the subject is willing to maintain the same therapeutic regimen and doses from the time of screening to the time of the first follow-up bronchoscopy with airway mucosal (Study Day 28 for Cohort 1; Study Day 84 for Cohort 2);
  • Pre-bronchodilator FEV1/forced vital capacity (FVC) ratio that is below the age-adjusted normal limit as defined by the 2007 National Heart Lung and Blood Institute Asthma guidelines (Appendix D) and post-bronchodilator FEV1 ≥ 65% at screening;
  • Must have ≥ 2.5% eosinophils in sputum;
  • Have had no hospitalizations due to asthma in the last year prior to screening;
  • Women of , unless surgically sterile or at least 1 year , must use 2 effective methods of avoiding pregnancy
  • Able to complete the follow-up period as required by the protocol;
  • Willing to forego other forms of experimental treatment and study procedures during the study and during an 84-day period after the last dose of study drug;
  • Able to provide spirometric readings that meet ATS standards

Exclusion criteria

Exclusion Criteria:

  • Participation in any previous MEDI-563 clinical study;
  • Known history of allergy or adverse reactions to any component of the study drug formulation;
  • Lung disease other than asthma (eg, , cystic fibrosis, eosinophilic pneumonia);
  • Current use of any systemic or inhaled drugs [oral (up to a maximum dose of 10 mg/day or 20 mg every other day) and inhaled are allowed if dose has been stable for at least 4 weeks prior to study drug administration on Study Day 0].
  • Current use of any β-blocker (eg, propranolol);
  • Acute illnesses or evidence of active infection, such as fever ≥ 38.0ºC (100.5ºF) at screening and through the time of the study drug administration on Study Day 0;
  • Receipt of any drug therapy, intravenous immunoglobulin (IVIG), or monoclonal therapy (eg, Xolair) within 30 days or within 5-half lives prior to study drug administration on Study Day 0 through End of Study/Study Termination (Study Day 84 for Cohort 1 or Study Day 140 for Cohort 2);
  • Pregnancy (women of must have a negative serum pregnancy test at screening and a negative urine pregnancy test prior to study drug administration on Study Day 0);
  • Breastfeeding or lactating;
  • History of alcohol or drug abuse \< 1 year prior to Study Day 0;
  • History of cancer, apart from basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy > 1 year prior to Study Day 0;
  • History of a previous episode of active TB or a positive TB skin test without completion of an appropriate course of treatment;
  • A history of coagulation disorders that would contraindicate mucosal ;
  • History of immunodeficiency or infection with -1, HIV-2, or hepatitis A, B, or C virus;
  • History of use of tobacco products within 2 years of baseline (Study Day 0) or history of smoking ≥ 10 pack-years;
  • Elective surgery planned from the time of screening through first follow-up bronchoscopy with airway mucosal biopsies (Study Day 28 or Study Day 84, as applicable);
  • Evidence of any systemic disease or respiratory disease (other than asthma), history of any disease, or any finding upon physical examination, screening laboratory test, chest X-ray (CXR), or that, in the opinion of the investigator or medical monitor, may compromise the safety of the subject in the study or confound the analysis of the study results;
  • Any employee of the research site who is involved with the conduct of the study;
  • History of lidocaine allergy
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    1

    MEDI-563

    Drug: MEDI-563

  • Experimental
    2

    MEDI-563

    Drug: MEDI-563

  • Placebo comparator
    4

    Placebo

    Other: Placebo Comp.

  • Placebo comparator
    5

    Placebo

    Other: Placebo

Interventions

  • 1.0 mg/kg IV: MEDI-563

  • 100 mg, 200 mg SC

  • OtherPlacebo Comp.

    Placebo SC

  • OtherPlacebo

    Placebo as a single IV infusion (Certain number of subjects)

06

What researchers measure

Primary outcomes

  1. Evaluate the safety and tolerability of MEDI-563 in adults with atopic asthma and evaluate the effects of MEDI-563 on eosinophil counts in airway mucosal biopsies 28 days after completion of dosing in adults with atopic asthma.

    Time frame: Study Day 84 or Day 140 - (dose-driven)

Secondary outcomes

  1. Evaluate the pharmacokinetics (PK) of MEDI-563 in adults with atopic asthma, and evaluate the immunogenicity (IM) of MEDI-563 in adults with atopic asthma.

    Time frame: Day 84 or 140

07

Study locations

11 sites
  • Research Site
    Denver, Colorado 80206, United States
  • Research Site
    Pittsburgh, Pennsylvania 15213, United States
  • Research Site
    Galveston, Texas 77555-0561, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Houston, Texas, United States
  • Research Site
    Madison, Wisconsin 53792, United States
  • Research Site
    Calgary, Alberta T2N4N1, Canada
  • Research Site
    Vancouver,, British Columbia, Canada
  • Research Site
    Hamilton, Ontario L8N3Z5, Canada
  • Research Site
    Montreal, Quebec H2X 2P4, Canada
  • Research Site
    Quebec, G1V4G5, Canada
08

References and documents

Publications

  • Chachi L, Diver S, Kaul H, Rebelatto MC, Boutrin A, Nisa P, Newbold P, Brightling C. Computational modelling prediction and clinical validation of impact of benralizumab on airway smooth muscle mass in asthma. Eur Respir J. 2019 Nov 14;54(5):1900930. doi: 10.1183/13993003.00930-2019. Print 2019 Nov. No abstract available. PubMed 31391226 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Jan 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2008
First posted
Apr 16, 2008
Start
Jan 2008
Primary completionActual
Jan 2011
CompletionActual
Mar 2011
Last update
Oct 10, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00659659
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
Apr 16, 2008
Start date
Jan 2008
Primary completion
Jan 2011
Completion
Mar 2011
Last update
Oct 10, 2012

Study contacts

David Gossage, M.D., MBA
study director · MedImmune LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion